Literature DB >> 23558025

Combination therapy in pulmonary arterial hypertension.

Richard N Channick1.   

Abstract

Many potential therapeutic options are now available for patients with pulmonary arterial hypertension. Interest has emerged in using therapies in various combinations. Retrospective experience has suggested that this approach is common and can be efficacious. Data are emerging supporting the benefit of combination therapy; however, limitations and questions remain about this strategy. This report reviewed the rationale for combination therapy and summarized the results from clinical trials.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23558025     DOI： 10.1016/j.amjcard.2013.01.320

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


  6 in total

Review 1.  Systematic Review of Randomized Controlled Trials of Endothelin Receptor Antagonists for Pulmonary Arterial Hypertension.

Authors:  Michael Kuntz; Miguel M Leiva-Juarez; Suvitesh Luthra
Journal:  Lung       Date:  2016-08-09       Impact factor: 2.584

2.  Fasudil and DETA NONOate, Loaded in a Peptide-Modified Liposomal Carrier, Slow PAH Progression upon Pulmonary Delivery.

Authors:  Jahidur Rashid; Kamrun Nahar; Snehal Raut; Ali Keshavarz; Fakhrul Ahsan
Journal:  Mol Pharm       Date:  2018-03-26       Impact factor: 4.939

3.  Cocktail of Superoxide Dismutase and Fasudil Encapsulated in Targeted Liposomes Slows PAH Progression at a Reduced Dosing Frequency.

Authors:  Nilesh Gupta; Jahidur Rashid; Eva Nozik-Grayck; Ivan F McMurtry; Kurt R Stenmark; Fakhrul Ahsan
Journal:  Mol Pharm       Date:  2017-02-17       Impact factor: 4.939

Review 4.  Pulmonary Arterial Hypertension: Combination Therapy in Practice.

Authors:  Marsha Burks; Simone Stickel; Nazzareno Galiè
Journal:  Am J Cardiovasc Drugs       Date:  2018-08       Impact factor: 3.571

5.  A meta-analysis of the safety and efficacy of bosentan therapy combined with prostacyclin analogues or phosphodiesterase type-5 inhibitors for pulmonary arterial hypertension.

Authors:  Zhan-Cui Dang; Bo Tang; Bin Li; Shou Liu; Ri-Li Ge; Zhan-Qiang Li; Dian-Xiang Lu
Journal:  Exp Ther Med       Date:  2019-10-29       Impact factor: 2.447

Review 6.  Superoxide Dismutase Administration: A Review of Proposed Human Uses.

Authors:  Arianna Carolina Rosa; Daniele Corsi; Niccolò Cavi; Natascia Bruni; Franco Dosio
Journal:  Molecules       Date:  2021-03-25       Impact factor: 4.411
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.